SCHEMBL3569694

SCHEMBL3569694

CN1CCN(c2ccc(NC=C3C(=O)Nc4cc(C(=O)c5ccc(N)cc5)ccc43)cc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.49
NTRK1 P04629 4/20 0.42
NTRK3 Q16288 1/20 0.42
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NTRK2 Q16620 3/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
ADRA2C P18825 1/20 0.40
GFER P55789 1/20 0.40
KMT2A Q03164 1/20 0.40
PTK2B Q14289 1/20 0.40
ESR2 Q92731 1/20 0.40
PIM1 P11309 1/20 0.39
HDAC3 O15379 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569691 0.94 CSF1R (0.49) CSF1RNTRK1NTRK3NPC1RAB9A
SCHEMBL3581952 0.93 CSF1R (0.43) CSF1RNTRK1NTRK3NPC1RAB9A
SCHEMBL3583080 0.92 CSF1R (0.47) CSF1RNTRK1NTRK3NPC1RAB9A
SCHEMBL3572137 0.90 CSF1R (0.52) CSF1RNTRK1NTRK3NPC1RAB9A
SCHEMBL3572136 0.90 CSF1R (0.52) CSF1RNTRK1NTRK3NPC1RAB9A
SCHEMBL3573947 0.90 CSF1R (0.48) CSF1RNPC1LMNASMN1; SMN2KDM4E
SCHEMBL3583076 0.89 CSF1R (0.47) CSF1RNTRK1NTRK3NPC1RAB9A
SCHEMBL3581951 0.87 CSF1R (0.43) CSF1RNTRK1NTRK3NPC1RAB9A
SCHEMBL3573380 0.85 CSF1R (0.49) CSF1RNTRK1NTRK3NPC1RAB9A
SCHEMBL3573384 0.85 CSF1R (0.49) CSF1RNTRK1NTRK3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US claimed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed
US-7749530-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-07-06 US disclosed
WO-2010075197-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2010-07-01 WO disclosed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 US disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 CSF1R 776/4885NTRK1 307/4885NTRK3 444/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 CSF1R 877/4885NTRK1 413/4885NTRK3 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.